



# Biotech Daily

Monday March 11, 2019

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: PARADIGM UP 10%; CYCLOPHARM DOWN 14%**
- \* **CE MARK FOR ADMEDUS CARDIOCEL 3D, VASCUCEL**
- \* **FEDERAL \$50m FOR ALFRED TRAUMATIC BRAIN INJURY MISSION**
- \* **VICTORIA FUNDS MELBOURNE UNI, CYNATA STEM CELL PROJECT**
- \* **ANTISENSE REQUESTS DUCHENNE MUSCULAR DYSTROPHY FUNDS HALT**
- \* **AVITA: 10 PRESENTATIONS AT AMERICAN BURNS MEETING**
- \* **MACH7 RESTRUCTURE: MIKE LAMPRON REPLACES CEO MIKE JACKMAN**
- \* **SANDON CAPITAL TAKES 8% OF IDT**
- \* **JAMORE, DANSHE TAKE 5% OF NUHEARA**
- \* **AUSTRALIAN ETHICAL TAKES 8.65% OF SOMNOMED**
- \* **AMPLIA APPOINTS PROF LARA LIPTON, PROF PHIL HANSBRO ADVISORS**

## MARKET REPORT

The Australian stock market fell 0.38 percent on Monday March 11, 2019, with the ASX200 down 23.6 points to 6,180.2 points. Eleven of the Biotech Daily Top 40 stocks were up, 18 fell, nine traded unchanged and two were untraded. All three Big Caps fell.

Paradigm was the best, up 14 cents or 10.4 percent to \$1.49, with 451,798 shares traded. Orthocell climbed 7.4 percent; Osprey and Patrys improved more than four percent; Ellex and Optiscan rose more than two percent; Medical Developments and Pro Medicus were up more than one percent; with Cynata, Neuren and Polynovo up less than one percent.

Cyclopharm led the falls, down 17.5 cents or 13.7 percent to \$1.105 with 451 shares traded, followed by Benitec down 12.5 percent to 14 cents with 164,251 shares traded.

Genetic Signatures lost 11.1 percent; Prana was down 6.7 percent; Immutep and Imugene fell five percent or more; Universal Biosensors retreated 4.55 percent; both Proteomics and Volpara were down 3.2 percent; Impedimed and Telix shed more than two percent, Actinogen, Clinuvel, Compumedics, LBT and Mesoblast were down more than one percent; with Cochlear, CSL, Nanosonics, Opthea and Resmed down less than one percent.

## ADMEDUS

Admedus says it has European Conformité Européenne (CE) mark approval for its Adapt tissue technologies Cardiocel three-dimensional (3D) and Vascucel.

Admedus said Cardiocel 3D was “the world’s first and only shaped and proven fully acellular collagen bioscaffold” for complex congenital defect repairs.

The company said it was used by cardiac surgeons during aortic arch reconstruction surgery to achieve a more natural shape and was calcification resistant.

Admedus said it would work with European opinion leaders in the first phase of its launch and would conduct a peer-to-peer education program in its second phase.

Admedus chief executive officer Wayne Paterson said that “obtaining CE Mark approval for the 3D portfolio is a further endorsement of the medical need and effectiveness of our 3D shaped collagen bioscaffold, a world first technology with proven anti-calcification properties and zero DNA”.

“Today’s approval of the 3D portfolio in Europe further reinforces the company’s focus on global strategic growth with geographic expansion into key markets and portfolio expansion of Adapt tissue technology products,” Mr Paterson said.

Admedus climbed 1.5 cents or 45.45 percent to 4.8 cents with 24.2 million shares traded.

## FEDERAL GOVERNMENT

The Federal Government says it will provide \$50 million over 10 years for coordinated traumatic brain injury medical research.

A media release from Federal Health Minister Greg Hunt said the Government would fund research into recovery after a traumatic brain injury, new technologies and effective care and treatment through the Medical Research Future Fund.

A spokesman for Mr Hunt told Biotech Daily that Perth’s Curtin University would be the project lead with 26 co-operating trauma centres, including Melbourne’s Alfred Hospital. The Government said that more than 20,000 Australians were hospitalized with a brain injury every year, from concussion from sport and road accidents, to an elderly person having a fall, with an estimated lifetime cost of up to \$4.8 million per patient.

Mr Hunt said symptoms ranged in severity, from cognition deficits to vegetative states and patients could experience “lack of emotional control, poor mental health, disrupted balance and sleep disturbances”.

## CYNATA THERAPEUTICS

Cynata says the Victoria Government has provided undisclosed funding to the University of Melbourne and Royal Women’s Hospital for research using its stemcells.

The State Government said 14 projects received grants from \$100,000 to \$500,000 from the Medical Research Accelerator Fund, with the University matching the grant funds.

Cynata said the University of Melbourne and Royal Women’s Hospital project would use its Cymerus mesenchymal stem cells in a study investigating advanced materials for the manufacture and delivery of highly potent mesenchymal stem cells.

Cynata product development head Dr Kilian Kelly said the materials being developed in the project “hold great potential for improving both the manufacturing of cells for therapeutic purposes and their delivery to patients”.

“As such, this could prove to be a highly impactful technology, both economically and clinically, and one that Cynata will be pleased to investigate for potential commercial use,” Dr Kelly said.

Cynata was up 1.5 cents or 0.95 percent to \$1.60.

### ANTISENSE THERAPEUTICS

Antisense has requested a trading halt “in respect of a placement to accelerate the development planned for ATL1102 in DMD”.

In January, Antisense said it had recruited five of nine patients in its Melbourne-based phase II trial of ATL1102 for Duchenne muscular dystrophy (DMD) (BD: Jan 20, 2019). Trading will resume on March 13, 2019 or on an earlier announcement.

Antisense last traded at 3.7 cents.

### AVITA MEDICAL

Avita says it 10 presentations on its Recell system for severe burns are scheduled for the American Burn Association meeting in Las Vegas from April 2 and April 5, 2019.

Avita said the presentations would “highlight positive results” from treatment using its Recell system in a range of patient populations and burn types.

The company said a presentation on Recell for paediatric patients was selected as a “best of the best” abstract.

Avita was unchanged at 14 cents with 9.5 million shares traded.

### MACH7 TECHNOLOGIES

Mach7 says a restructure to cut costs and accelerate sales will see chief operating officer Mike Lampron replace chief executive officer Mike Jackman, effective immediately.

Mach7 said that founder chief strategy officer Ravi Krishnan would expand from the Asia-pacific and Middle East regions to include the US.

The company said chief technology officer Eric Rice would move to a consulting role.

Mach7 said it would hire new staff in Asia and the US and would reallocate resources across geographic locations.

The company said the restructure would cut costs, accelerate sales growth and reduce labor costs and overheads.

Mach7 said it would enable it “to achieve cash flow break even from operations” for the next 12 months.

Mach7 fell two cents or 10 percent to 18 cents.

### IDT AUSTRALIA

Sandon Capital says it has increased its shareholding in IDT from 16,102,505 shares (6.6%) to 18,395,015 shares (7.8%).

The Sydney-based Sandon said that between June 7, 2018 and February 14, 2019, its trustee Fundhost bought 2,292,510 shares for \$171,617 or 7.5 cents a share.

IDT was up one cent or 6.9 percent to 15.5 cents.

### NUHEARA

Jamore Pty Ltd and the Danshe Super Fund have become substantial shareholders in Nuheara with 51,892,742 shares or 5.29 percent of the company.

In a substantial shareholder notice signed by director Daniel Di Paolo the Melbourne-based Jamore said that on February 22, 2019 it acquired 1,848,709 shares for \$144,199 or 7.8 cents a share and on March 4, 2019 it acquired 1,975,145 shares for \$140,235 or 7.1 cents a share.

Nuheara was up 0.1 cents or 1.5 percent to 6.9 cents with 5.2 million shares traded.

### SOMNOMED

Australian Ethical Investments says it has increased its substantial shareholding in Somnomed from 4,656,042 shares (7.48%) to 5,435,538 shares (8.65%).

Australian Ethical said that between July 18, 2018 and March 3, 2019 it sold shares on one occasion and bought shares on 22 dates with the single largest acquisition 145,833 shares for \$255,769 or \$1.75 a share.

Somnomed was untraded at \$1.75.

### AMPLIA THERAPEUTICS

Amplia says it has appointed Prof Lara Lipton and Prof Phil Hansbro to its advisory board.

Amplia said Associate Prof Lipton was a medical oncologist with experience with pancreatic cancer patients and worked currently as a clinical investigator with Cancer Trials Australia.

The company said Prof Hansbro was currently the director of Sydney's Centenary University of Technology Sydney Centre for Inflammation and was a respiratory disease researcher.

Amplia was untraded at 13 cents.